

Dedication

This meeting is taking place to celebrate Prof. Volker Diehl's 70th birthday and his life-time achievement in the field of Hodgkin Lymphoma. For his work he was awarded the *Bundesverdienstkreuz* this September by the German government, which is one of the highest national recognitions.

As we all know, Volker Diehl has made a stunning career, both as researcher in the biology of Hodgkin Lymphoma and as founder and former chairman of the German Hodgkin Study Group (GHSg). He clearly envisioned that improvements in this usually fatal malignancy would only be possible in the context of prospective randomized trials paralleled by scientific research projects. Today, the GHSg is in its 6th generation of clinical trials and has just opened the 18th large prospectively randomized study, HD18. In addition, numerous phase-I and phase-II studies were conducted. More than 15.000 Hodgkin patients have been treated in GHSg trials with more than 400 centers contributing here in Germany and countries such as the Czech Republic, Switzerland, The Netherlands, Austria, Denmark and others. Volker Diehl has always played a pivotal role in the GHSg. His work has resulted in important achievements in the treatment of Hodgkin Lymphoma and will continue to do so in the years to come.



Symposium Hosts

Prof. Dr. Andreas Engert
Klinik I für Innere Medizin
Uniklinik Köln
Kerpener Straße 62
50924 Köln
Germany

Prof. Dr. Michael Hallek, Direktor
Klinik I für Innere Medizin
Uniklinik Köln
Kerpener Straße 62
50924 Köln
Germany

Management

Gabriele Hanke
Travel & Congress Activities
Marienburger Str. 8
40883 Ratingen
Germany



Welcome

Let me please welcome you to this International Symposium on *New Frontiers in Hodgkin Lymphoma* which is taking place to honor Prof. Dr. Volker Diehl. As you probably know, Volker has turned 70 this year and has been awarded the *Bundesverdienstkreuz* by the German Government for his life-term achievements in the field. For the meeting, we have chosen the Hyatt Cologne offering a wonderful communicative environment for scientific discussion and networking. The presentations focus on new aspects in the biology of HL, translational approaches aimed at the development of new treatment strategies, the latest results and perspectives as well as some new approaches in handling this fascinating disease.

We very much hope that this focused symposium will give a comprehensive update on major achievements in the field of Hodgkin Lymphoma and point out trends and tasks for future activity. On behalf of my teacher and friend, Volker Diehl, I cordially welcome you to this meeting.

Köln, September 2008

Prof. Dr. Andreas Engert
Chairman of the GHSg

SCIENTIFIC SYMPOSIUM

New Frontiers in Hodgkin Lymphoma

Hyatt Regency Köln

September 12, 2008

Acknowledgements

The Organizing Committee wishes to express its appreciation and gratitude to the



Helfen. Forschen. Informieren.
Deutsche Krebshilfe



Deutsche Forschungsgemeinschaft



Bundesministerium für Bildung und Forschung

Bundesministerium für Bildung und Forschung

We thank the following pharmaceutical companies:

Amgen GmbH
Celgene GmbH
Mundipharma
Ortho Biotech Div. of Janssen-Cilag GmbH
Roche Pharma AG

Program

Hyatt Regency Köln | "Rheinsaal 2"

Welcome, A. Engert | 09:00–09:10

Session I | 09:10–10:30

09:10–10:30 HRS-cells and chronic inflammation	Chair: M. Krönke, Ch. von Kalle
09:10–09:30 Molecular genetics of HRS-cells	H. Stein
09:30–09:50 Biology of HL	D. Re
09:50–10:10 Epigenetic reprogramming	M. Hummel
10:10–10:30 Proteomics	N. v. Neuhoff

Coffee Break | 10:30–10:50

Session II | 10:50–11:50

10:50–11:50 Translational approaches	Chair: Ch. Fonatsch, J. Wolf
10:50–11:10 Monoclonal Antibodies	B. Böll
11:10–11:30 Targeted Treatment	S. Mathas
11:30–11:50 Is there a prognostic impact of biological markers?	D. Hasenclever

Laudationes | 11:50–12:10

Lunch | 12:10–13:00

Session III | 13:00–14:20

13:00–14:20 Modern Treatment of HL	Chair: W. Lehmacher, H. Tesch
13:00–13:20 The role of models in the design of modern chemotherapy	M. Löffler
13:20–13:40 Does PET change the management of HL?	M. Hutchings
13:40–14:00 Chemo alone or combined modality in early-stages?	J. Raemaekers
14:00–14:20 The advent and impact of BEACOPP	M. Pfreundschuh

Coffee Break | 14:20–14:30

Session IV | 14:30–16:00

14:30–16:00 Perspectives	Chair: M. Hallek, M. Dietlein
14:30–14:50 The new trial generation of the GHSG	A. Engert
14:50–15:10 The future of autologous and allogeneic transplant in HL	N. Schmitz
15:10–15:30 New drugs in clinical trials	P. Borchmann
15:30–15:50 Survivorship	S. Horning
15:50–16:00 What is left to do?	V. Diehl

Adjourn | 16:15

Speakers and Chairmen

Böll, Boris: boris.boell@uk-koeln.de
Borchmann, Peter: peter.borchmann@uni-koeln.de
Dietlein, Markus: markus.dietlein@uni-koeln.de
Engert, Andreas: a.engert@uni-koeln.de
Fonatsch, Christa: christa.fonatsch@meduniwien.ac.at
Hallek, Michael: michael.hallek@uni-koeln.de
Hasenclever, Dirk: Dirk.Hasenclever@imise.uni-leipzig.de
Horning, MD, Sandra J.: sjh@stanford.edu
Hummel, Michael: michael.hummel@charite.de
Hutchings, MD, Martin: hutchings@dadlnet.dk
von Kalle, Christof: christof.kalle@nct-heidelberg.de
Krönke, Martin: Martin.Kroenke@medizin.uni-koeln.de
Lehmacher, Walter: walter.lehmacher@uk-koeln.de
Löffler, Markus: markus.loeffler@imise.uni-leipzig.de
Mathas, Stephan: stephan.mathas@charite.de
von Neuhoff, Nils: neuhoff.nils.von@mh-hannover.de
Pfreundschuh, Michael: michael.pfreundschuh@uniklinik-saarland.de
Raemaekers, MD, PhD, John: J.Raemaekers@HEMAT.umcn.nl
Re, Daniel: daniel.re@ch-antibes.fr
Schmitz, Norbert: n.schmitz@asklepios.com
Stein, Harald: Harald.Stein@charite.de
Tesch, Hans: hans.tesch@tesionmail.de
Wolf, Jürgen: juergen.wolf@uk-koeln.de

Diehl, Volker: v.diehl@uni-koeln.de